cobas EGFR Mutation Test, v2 CE- IVD and cobas cfDNA Sample Preparation Kit 의 안전성 경고

Department of Health에 따르면, 해당 안전성 경고 는 Hong Kong 에서 Roche Diagnostics 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

안전성 경고는 의료기기 제품과 관련된 중요한 정보와 권고사항을 담고 있습니다. 물론 안전성 경고가 배포되었다고 해서 해당 제품이 무조건 안전하지 않은 제품이라는 것은 아닙니다. 보건의료업계 종사자와 의료기기 사용자들에게 배포되는 안전성 경고에는 회수(recall)도 포함될 수 있습니다. 제조사가 안전성 경고를 작성하기도 하지만, 보건당국에서 작성하는 경우도 있습니다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Safety alert
  • 날짜
    2016-04-18
  • 사례 출판 날짜
    2016-04-18
  • 사례 국가
  • 사례 출처
    DH
  • 사례 출처 URL
  • 비고 / 경고
    Hong Kong data is current through September 2018. All of the data comes from the Department of Health (Hong Kong), except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Hong Kong.
  • 데이터 추가 비고
    Medical Device Safety Alert
  • 원인
    Medical device safety alert: roche diagnostics cobas egfr mutation test, v2 ce- ivd and cobas cfdna sample preparation kit medical device manufacturer, roche diagnostics, has issued a medical device safety alert concerning its cobas egfr mutation test, v2 ce- ivd and cobas cfdna sample preparation kit. according to the manufacturer, several mutations (l858r, exon 19 deletion, t790m) inconsistently generated “no mutation detected” (i.E. false negative) results with the cobas egfr mutation test, v2 when utilising the cobas cfdna sample preparation kit during internal studies using contrived plasma specimens. there is no impact when using the cobas dna sample preparation kit with the cobas egfr mutation test, v2 to test formalin-fixed paraffin-embedded tumour (ffpet) tissue samples. patients with a false negative result for the mutations may be denied the prospect of prolongation of disease control and survival (8-12 months). the manufacturer will update the instructions for use (ifu) for the cobas egfr mutation test, v2 and cobas cfdna sample preparation kit to revise the handling of the eluate for plasma specimens prior to amplification and detection. users are advised to follow the revised instruction until the updated ifu become available. according to the local supplier, the affected products are distributed in hong kong. if you are in possession of the affected products, please contact your supplier for necessary actions. posted on 18 april 2016.

Device

  • 모델명 / 제조번호(시리얼번호)
  • 제품 설명
    Medical Device Safety Alert: Roche Diagnostics cobas EGFR Mutation Test, v2 CE- IVD and cobas cfDNA Sample Preparation Kit
  • Manufacturer

Manufacturer